VK2735 Research# VK2735's evidence base consists of phase 2 trials: VENTURE (subcutaneous): 176 adults with obesity, 13 weeks, up to 14.7% weight loss from baseline (placebo-adjusted 13.1%) VENTURE-Oral: Oral tablet formulation, 13 weeks, up to 12.2% weight loss vs 1.3% placebo Phase 3 VANQUISH program: Planned but not yet initiated at time of writing Evidence level: Low -- promising phase 2 data only, short duration, small sample sizes, no head-to-head comparisons
Any adverse effects should be reported through the MHRA Yellow Card scheme
For many, weight loss brings positive changes that help with sexual function
For this reason, babies with clefts should be burped often
Aids immune health and nutrient metabolism
However, most insurance providers require proof that you have tried other solutions, such as physical therapy, without success before you turn to surgery